Methods and compositions for treating recurrent cancer

Abstract

The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.

What is claimed is: 
     
       1. A method of treating a recurrent ovarian, peritoneal, or fallopian tube cancer in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about three months prior to the initiation of the treatment, wherein the nanoparticle composition is not administered in conjunction with a platinum-based agent, and wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 5 mg/m 2  to about 400 mg/m 2  every three weeks. 
     
     
       2. The method of  claim 1 , wherein the recurrent ovarian, peritoneal, or fallopian cancer is platinum-sensitive. 
     
     
       3. The method of  claim 1 , wherein the individual has received a prior platinum-based chemotherapy and has a treatment free interval of more than about 12 months since the completion of the platinum-based chemotherapy. 
     
     
       4. The method of  claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered alone. 
     
     
       5. The method of  claim 1 , wherein the taxane is paclitaxel. 
     
     
       6. The method of  claim 1 , wherein the carrier protein is albumin. 
     
     
       7. The method of  claim 1 , wherein the nanoparticles in the composition have an average or mean diameter of no greater than about 200 nm. 
     
     
       8. The method of  claim 7 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is Nab-paclitaxel. 
     
     
       9. The method of  claim 1 , wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about 6 months prior to the initiation of the treatment. 
     
     
       10. The method of  claim 1 , wherein the individual does not show a symptom of hypersensitivity prior to the initiation of the treatment. 
     
     
       11. The method of  claim 1 , wherein the individual does not show a symptom resulting from the recurrent cancer upon completion of the treatment. 
     
     
       12. The method of  claim 1 , wherein the individual has a reduced CA-125 level upon completion of the treatment. 
     
     
       13. The method of  claim 1 , wherein the nanoparticles comprise the taxane coated with a coating comprising the carrier protein. 
     
     
       14. The method of  claim 13 , wherein the taxane is paclitaxel. 
     
     
       15. The method of  claim 13 , wherein the carrier protein is albumin. 
     
     
       16. The method of  claim 1 , wherein the nanoparticles composition is administered intravenously. 
     
     
       17. The method of  claim 1 , wherein the nanoparticle composition is administered intraperitoneally. 
     
     
       18. The method of  claim 7 , wherein the nanoparticles comprise the taxane coated with a coating comprising the carrier protein. 
     
     
       19. The method of  claim 18 , wherein the taxane is paclitaxel. 
     
     
       20. The method of  claim 18 , wherein the carrier protein is albumin. 
     
     
       21. The method of  claim 19 , wherein the carrier protein is albumin. 
     
     
       22. The method of  claim 7 , wherein the nanoparticles composition is administered intravenously. 
     
     
       23. The method of  claim 7 , wherein the nanoparticle composition is administered intraperitoneally. 
     
     
       24. The method of  claim 8 , wherein the nanoparticles composition is administered intravenously. 
     
     
       25. The method of  claim 8 , wherein the nanoparticle composition is administered intraperitoneally. 
     
     
       26. The method of  claim 21 , wherein the nanoparticles composition is administered intravenously. 
     
     
       27. The method of  claim 21 , wherein the nanoparticle composition is administered intraperitoneally. 
     
     
       28. The method of  claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 180 mg/m 2  to about 300 mg/m 2  every three weeks. 
     
     
       29. The method of  claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 260 mg/m 2  every three weeks.